Merck & Co., Inc. gained the delta-like ligand 3 (DLL3)-targeting T-cell engager MK-6070 earlier this year through the $680m acquisition of Harpoon Therapeutics, and now the company is tapping Daiichi Sankyo Co., Ltd. as a partner to help develop and commercialize the drug.
Key Takeaways
- Daiichi will pay Merck $170m upfront to co-develop and co-commercialize the delta-like ligand 3 (DLL3) targeting T-cell engager MK-6070.
- The companies have their eye on the combination of MK-6070 with the antibody-drug conjugate ifinatamab deruxtecan, which they are already partnered on
Merck and Daiichi announced a co-development and co-commercialization agreement for MK-6070 on 6 August, driven in part by the companies’ interest in studying the drug in combination with an